home / stock / sva:cc / sva:cc news

SVA:CC News and Press, Sernova Corp. From 06/13/25

Stock Information
Company Name: Sernova Corp.
Stock Symbol: SVA:CC
Market: TSXVC
Website: sernova.com
Menu
SVA:CC SVA:CC Quote SVA:CC Short SVA:CC News SVA:CC Articles SVA:CC Message Board
Get SVA:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
SVA:CC - Expected Canadian Company Earnings on Friday, June 13th, 2025

Sernova Biotherapeutics Inc. (SVA:CA) is expected to report for Q2 2025 Moovly Media Inc. (MVY:CA) is expected to report for quarter end 2025-03-31 BriaCell Therapeutics Corp. (BCT:CA) is expected to report $-2.43 for Q3 2025 Santacruz Silver Mining Ltd. (SCZ:CA) is expected to report...
SVA:CC - Sernova Appoints Jonathan Rigby as Interim Chair

LONDON, Ontario and BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced the appo...

SVA:CC - Chair of Sernova Biotherapeutics Resigns

LONDON, Ontario and BOSTON, May 26, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced the resig...

SVA:CC - Sernova Biotherapeutics Appoints World-Class Clinical Advisory Board to Support Development of Cell Pouch Bio-hybrid Organ as Functional Cure for Type 1 Diabetes

LONDON, Ontario and BOSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced the forma...
SVA:CC - Sernova Biotherapeutics Provides Positive Interim Data from Ongoing Phase 1/2 Clinical Trial of Cell Pouch Bio-hybrid Organ in Patients Living with Type 1 Diabetes

Clinical Study on Track to Meet its Primary and Secondary Endpoints Data Demonstrate That Metabolic Measures Improve with Cumulative Quantities of Transplanted Donor Islets Data Demonstrate Islet Engraftment in Cell Pouch and Islet Functionality, Including C-Peptide Production ...

SVA:CC - Sernova Biotherapeutics Secures $4 Million Loan to Further Advance its Clinical Development Plans

LONDON, Ontario and BOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing it’s Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced...

SVA:CC - Sernova Biotherapeutics Cell Pouch Bio-hybrid Organ to be Highlighted at Cell & Gene Meeting on the Med

LONDON, Ontario and BOSTON, April 15, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company, today announced that the Company’s Cell Pouch Bio-hybrid Organ in clinical development as a functional cure for type ...
SVA:CC - Sernova Biotherapeutics Provides Update on Phase 1/2 Clinical Trial of Cell Pouch(TM) Bio-Hybrid Organ for Treatment of Type 1 Diabetes

DSMB supports advancement for Sernova’s clinical trial Study is on track to meet key clinical trial endpoints LONDON, Ontario and BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine co...

SVA:CC - Expected earnings - Sernova Biotherapeutics Inc.

Sernova Biotherapeutics Inc. (SVA:CA) is expected to report for Q1 2025

SVA:CC - Sernova Biotherapeutics Appoints Pericles Calias, Ph.D. as Chief Development Officer and Head of R&D

LONDON, Ontario and BOSTON, March 10, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing it’s Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced...
Previous 10 Next 10